44
Participants
Start Date
December 31, 2013
Primary Completion Date
February 28, 2015
Study Completion Date
February 28, 2017
Bortezomib
"Patients will receive two cycles of Bortezomib (Velcade®) at an interval of three months.~Each cycle will consist of intravenously administered (within 3-5 seconds) Bortezomib 1.3 mg/m2 twice weekly on days 1, 4, 8 and 11."
Placebo
"Patients will receive two cycles of Placebo (NaCl solution) at an interval of three months.~Each cycle will consist of intravenously administered (within 3-5 seconds) Placebo twice weekly on days 1, 4, 8 and 11."
Medical University of Vienna, Department of Nephrology and Dialysis, Vienna
Medical University Innsbruck
OTHER
Medical University of Vienna
OTHER